ARP is a Queensland, Australia based, unlisted public company. ARP owns the rights to commercialize Acteev®, a novel formulation that has patent protection pending. ARP is commercializing Acteev® for a variety of human and animal degenerative joint conditions including osteoarthritis, cervical and lumbar spondylitis.
ARP’s lead product is for the treatment of osteoarthritis and may prove to be the world’s first natural and topical treatment providing long-term results with no known side effects.
ARP is currently searching for marketing and distribution partners worldwide.
ARP involvement in a Menzies Research Institute Arthritis study recieves news coverage... view here
ARP launches the first product based on Acteev® technology in New Zealand ... more
Arthritis Relief Plus receives positive results from a trial comparing Acteev® to a placebo... more
Arthritis Relief Plus initiates clinical trial with Stanford University
Today Arthritis Relief Plus Limited announced their collaboration with the Stanford Center on Longevity to investigate the long term effect of Acteev® on osteoarthritis... more
A Pilot Trial at Stanford University commences investigating the ability of ACTEEV® to reduce pain associated with Delayed Onset Muscle Soreness (DOMS).
Arthritis Relief Plus Limited will be attending the BIO International Conference in San Diego with the specific goal of engaging potential distribution and marketing partners from around the world.
The Arthritis Relief Plus Limited patent receives a clear International Preliminary Report on Patentability (IPRP) stating that all claims are novel and inventive over the prior art.